Introduction
Enfuvirtide (formerly T-20), the first approved HIV fusion inhibitor has demonstrated potent activity against multiresistant HIV-1 strains. 1, 2 Enfuvirtide is also the only antiretroviral (ARV) drug to be administrated by injection (90 mg subcutaneously twice a day).
The aim of this study was to evaluate the quality of life and the intensity of the injection site reactions during the first 6 months of treatment with enfuvirtide according to the counseling and training provided by nurses and physicians. In this prospective, 6-month cohort, 61 HIV-1 infected adult patients starting enfuvirtide have been included. At baseline, 82% of the patients have either read information documents (23%) or received counseling (59%); 18% were self-injectors, 27.8% had a dual disposition (self-injector + third person), and 49.2% were injected by a third person. At month 6, among the 43 patients still on enfuvirtide, 59% have had no change in injection disposition, and 52% have the dual disposition. Quality of life and enfuvirtide acceptance improved during 6 months. With adequate education and choice of injection dispositions, treatment with enfuvirtide canfrom 18 French HIV centers have been included in a prospective cohort (SURCOUF study). Enfuvirtide was given at standard dose as part of an optimized background regimen chosen by the physician in charge of the patient. At baseline (day 1), demographic data, weight, size, history of lipodystrophy, optimized regimen, plasma HIV-RNA, and CD4 count were recorded. Patients completed a self-questionnaire on quality of life and management of enfuvirtide injections. Quality of life and enfuvirtide satisfaction were evaluated on an analogue scale. At each visit, that is, day 15 and months (M) 1, 2, 3, and 6, ISRs, changes in optimized and enfuvirtide treatment, and if available, CD4 count and plasma HIV-1 RNA were recorded and the patients completed the self-questionnaire on adverse events and quality of life. The aim of the study was to assess the quality of life; the acceptance of enfuvirtide; and the frequency, type, and intensity of ISRs during the first 6 months of treatment with enfuvirtide according to the administration guidelines and the counseling provided by nurses and physicians, the immunovirological status, and the presence or not of lipodystrophy.
All data were collected on a Microsoft Access 2000 database. Continuous parameters reported as medians were analyzed descriptively. All statistical tests had a significant cutoff of 5% (2-sided), and were run on Epi Info v 6.04.
Results
Of the 61 adult patients, 46 (75%) were male, with a median age of 44 years (range, 31-70). Optimized regimen associated with enfuvirtide was a combination of nucleoside reverse transcriptase inhibitors (NRTIs) and ritonavir-boosted protease inhibitor (PI) in two thirds of the cases (n = 41); a dual ritonavir-boosted PI in 6 patients, of whom 4 received ritonavir-boosted tipranavir plus fosamprenavir; a combination of nonnucleoside reverse transcriptase inhibitor (NNRTI) and ritonavir-boosted PI in 3 patients; a tritherapy of NRTIs in 10; and a combination of NRTIs and NNRTI in 1 patient. Tipranavir was part of the optimized regimen in 20 of the 50 patients receiving a PI-containing regimen. At baseline, the median CD4 count was 110/mm 3 (range, 1-567); 22 patients (36%) had a CD4 count of less than 50 cells/ mm 3 ; the median HIV viral load was 4.9 log 10 copies/mL (range, 2.7-6.4). The median body mass index was 21.4 (range, 13.6-31.5). Clinical lipodystrophic syndrome was present in 47.5% of the patients, which was most often a lipoatrophy in cheek (72.4%), buttock (65.5%), and limbs (68.9%); 11 patients (37.9%) reported an abdominal enlargement.
During the follow-up, enfuvirtide was discontinued in 18 patients (29.5%) for the following reasons: death (all before M2), n = 4; ISR, n = 3 (at M1, M3, and M5); virologic failure, n = 3; clinical worsening, n = 1; treatment simplification, n = 2; and patient decision or nonobservance, n = 5. Before starting enfuvirtide injections, 14 patients (23%) read the information documents, and 36 patients (59%) met a nurse for counseling and training, in median during nearly 1 hour (52 minutes; range, 15-105 minutes).
Patients received information about enfuvirtide, in median 45 days (range, 1-270) before the start of the treatment. At baseline, the quality of life was bad/rather bad for 21.3% of the participants, and difficulties with enfuvirtide were feared by 27.8% of them. Injections were performed only by a nurse or a third person, only by the patients, and both by the patient and a third person in 51.5%, 18%, and 29.5% of patients, respectively. The evolution of enfuvirtide injection modalities and sites over time is shown in Table 1 . Information was available for 58/61 patients at treatment initiation and for 35/43 at M6. The majority of patients (59%) did not change their injection modalities between baseline and M6. Among the 11 self-injectors at baseline, 8 (73%) were still on treatment at M6, 4/8 (50%) with selfinjection; 4/8 changed their method of injection-3/8 (37.5%) to the dual injection process (self-injection + third person) and 1 to injections performed by a nurse. Among the 17 patients with the dual injection modalities at baseline, 11 (65%) were still on treatment at M6: 7/11 (64%) with the dual process and 4/11 (36%) with injections performed by a third person. Among the 30 patients with injections performed by a third person at baseline, 14 (47%) were still on treatment at M6: 1 switched to self-injection, 7/14 (50%) switched to the dual process, and 6/14 (43%) had no change.
At baseline, patients planned to inject enfuvirtide in the abdomen (78%), thighs (80%), upper arms (65%), back (38%), and buttock (45%). After 6 months of treatment, back and buttock were quite frequently used by 57% and 51% of the patients, respectively, whereas the abdomen was the most frequent site of injection (83%). ISRs at M3 were more frequent, although not statistically significant, when injections were performed by the patient (83%) as compared with the case when injections were performed solely by a third person (57%). The number of ISRs remained quite stable over time: the percentage of patients with 3 or less cutaneous symptoms varied from 46.5% at M1 to 24% at M3 and 37% at M6, and the percentage with 4 to 10 symptoms varied from 12% at M1 to 18% at M3 and 16% at M6. No patient had more than 10 injection site manifestations at M1 and M6. Clinical lipodystrophy did not increase the frequency of ISRs, which were seen in 64% and 69% of lipodystrophic patients at M1 and M3, respectively, compared with 69% and 56% of nonlipodystrophic patients at M1 and M3, respectively (not statistically significant). The nature, intensity and frequency of the injection reactions are detailed in Table 2 .
Quality of life improved over time: it was considered as good/very good by 38% at baseline, 54% at M1, 52% at M3, and 63% of the patients on therapy at M6, and as bad/rather bad by 21.3% at baseline, 15% at M1, 12% at M3, and 14% at M6.
Acceptance of enfuvirtide injection improved over time: it was considered as good/very good in 41% of the patients at baseline, and in 60%, 67%, and 74% of the patients at M1, M3, and M6, respectively. Quality of life and enfuvirtide acceptance were not different in the total population and the group of patients with counseling and training. In the limited subgroup of patients without counseling and training (n = 8), only 1 patient was still on treatment at M3. On treatment, median change in CD4 count was +78 cells/mm 3 (range -64 to +362) at M3 and +98 cells/mm 3 (range, -81 to +552) at M6. Plasma HIV-1 RNA was below 400 copies/mL in 75% (30/45) and 66% (23/35) of the patients at M3 and M6, respectively.
Discussion
During 6 months of treatment with enfuvirtide, quality of life improved in patients who remained on enfuvirtide. The results of the SURCOUF study are consistent with previously published results. [4] [5] [6] [7] In TORO (T-20 vs Optimized Regimen Only), enfuvirtide in addition to an optimized regimen improved the quality of life when self-administrated for up to 24 weeks by those experienced in ARV treatment. 8 The education and support of nurses before and during the treatment as well as the help of a third SURCOUF Study / Allavena et al 189 person to perform the injections play a role in the better acceptance of enfuvirtide. [9] [10] [11] In our study, nearly three quarters of the patients have either been informed and trained by a nurse or read the information documents before starting the enfuvirtide injections, but 27.8% of the patients feared difficulties with injections. In the study by Horne et al, 9 32% of the patients agreed that the drawbacks of self-injectable therapy would outweigh the benefit of therapy. The impact of a subcutaneous injection treatment on quality of life is difficult to evaluate. 12 Green found only low to moderate correlations between a subcutaneous injection survey test and the MOS-HIV (Medical Outcomes Study health status questionnaire for HIV) test that is usually used to assess the relationship between treatment satisfaction and quality of life in the HIV-infected population. 13 In this study, patients' experiences with self-injection were not strongly associated with health-related quality of life. In our study, in which most participants were heavily ARV-experienced, the positive findings are the improvement of quality of life as well as acceptance of enfuvirtide injections over time, with a low rate of treatment discontinuation related to patient decision and/or enfuvirtide intolerance. Only 18% of the patients were exclusively self-injectors at treatment initiation, but the proportion of patients in whom injections were done in alternating fashion with a third person increased over 6 months: more than half of the patients, over time, had recourse to a relative or a nurse for injections. This modality offers greater flexibility, in that the patient is not fully dependent on a third person for injections, but at the same time, being injected by someone else offers an increase in the availability of injection sites. This possibility of having injections in difficult-to-reach sites did not, however, decrease the frequency, nature, type, and severity of ISRs in our study. Furthermore, the help of a nurse to inject enfuvirtide once or twice a day and a closer follow-up may improve the overall adherence to ARV treatment in patients who are more likely to have difficulties in dealing alone with their treatment for social or psychological reasons. [14] [15] [16] Improvement in quality of life has been shown to be related to the improvement of surrogate markers of HIV disease, including increase in CD4 count and low HIV viremia. 17 The immunovirological efficacy of enfuvirtide outweighs the ISRs and all the inconveniences related to its administration. Indeed, 74% of the patients had a good/very good quality of life after 6 months of therapy, with 66% having an undetectable viral load. The bias is that patients who are still on therapy with enfuvirtide at M6 are those with a clinical and/or biological benefit. Despite the small number of participants, lipodystrophy and low body mass index did not seem to influence tolerability.
As the nursing staff has a critical role in the management of an ARV therapy, including enfuvirtide, they must be very familiar with the different aspects of enfuvirtide-both the technical aspects of preparation and injection, and the scientific knowledge, mode of action, efficacy, and tolerability of the drug. It is important that healthcare professionals can provide guidance to patients before and during the course of the treatment with enfuvirtide, with complete instructions on the use of enfuvirtide and periodic support. Nurse education and assessment should also include a discussion on the site selection for injections, rotations of sites, a review on the preparation and reconstitution phase and the injection procedure, a report on ISRs, and if necessary, counseling on the best ways to decrease local intolerance. 16 Because over time more patients tend to self-inject enfuvirtide (at least 1 of the 2 daily injections), education from nurses along the course of treatment remains essential to avoid weariness, discouragement, or misunderstanding that can lead to lack of adherence or even treatment interruption.
Although there is no randomized comparison of enfuvirtide with a control group, although the quality of life is measured by a visual analogue scale rather than a validated questionnaire, and although it is difficult to draw a conclusion about the effect of the counseling and training intervention, this study eventually shows that in a real-life setting, adequate support can improve the tolerability and acceptance of treatment with enfuvirtide.
Conclusion
The findings of this study suggest that with adequate education and support, patients are able to manage a treatment with injectable medication over time. A powerful treatment can lead to an improvement in acceptance and quality of life, even if the method of administration is restrictive. One of the key ingredients in the long-term success of such a treatment, including enfuvirtide, is the counseling and guidance provided by nurses and physicians, not only prior to starting but also throughout the therapy.
